32 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22650 | vaccine, diarrhea, clostridium | Multiple | Pfizer | IJB_2672 | Trial closed | A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older | 3 | 3 | |||
| 22850 | Metastatic, any tumors | Solid tumors | Institut Jules Bordet | IJB_2728 | Trial open for recruitment | Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention | |||||
| 22657 | Metastatic, Biopsy mandatory | Nuria Kotecki | Multiple | Lilly | IJB_2732 | Trial closed | A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti-PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors | Nuria.Kotecki@hubruxelles.be | 1/1b | 1 | |
| 22710 | Metastatic or non-resecable. Refractory to platinum regimen | Alain Hendlisz | Multiple | Institut Jules Bordet | IJB-MULTI-MIME-A-2017 | Trial closed | IJB-MULTI-MIME-A-2017 Multiorgan Metabolic imaging response assessment of Abemaciclib: the MiMe-A trial | alain.hendlisz@hubruxelles.be | 2 | 2 | |
| 22662 | second line, RECIST 1.1, Biopsy | Philippe Aftimos | Multiple | Incyte Corporate | INCAGN1876-201 | Trial closed | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | philippe.aftimos@hubruxelles.be | 1 | 1 | |
| 22640 | Metastatic, Biopsy mandatory | Christiane Jungels | Multiple | Incyte Corporate | INCB 01158-203 | Trial closed | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors. (INCB01158-203) | christiane.jungels@hubruxelles.be | 1 | 1 | |
| 22655 | Any line | Ahmad Hussein Awada | Solid tumors | Incyte Corporate | INCB59872-101 | Trial closed | A Phase 1/2, Open-Label, Dose-Escalation / Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies | ahmad.awada@hubruxelles.be | 1/2 | 1 | |
| 22849 | Be a parent or close relative of a child between the ages of 3 and 18 confronted with parental cancer, any tumors | Solid tumors | Intervention destinée aux parents | Trial open for recruitment | L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité | ||||||
| 29371 | Laura Polastro | Endometrium | MSD (Merck Sharp & Dohme) | KEYNOTEC93 | Trial closed | A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTEC93/GOG-3064/ENGOT-en15) | laura.polastro@hubruxelles.be | 3 | 3 | ||
| 22669 | Metastatic, Biopsy mandatory | Christiane Jungels | Multiple | Merus | MCLA-158-CL01 | Trial open for recruitment | Phase 1 dose escalation and cohort expansion study evaluating single-agent MCLA-158 in metastatic colorectal cancer and other advanced solid tumors | christiane.jungels@hubruxelles.be | 1 | 1 | |
| 28450 | Laura Polastro | Uterus | Merck | Merck - MS200647_0017 - TRAP0017 | Trial closed | A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-Containing Chemotherapy | laura.polastro@hubruxelles.be | 2 | 2 | ||
| 29332 | Laura Polastro | Ovary | Merck | MK-3475-B96/KEYNOTE-B96/ENGOT-ov65 | Trial closed for recruitment | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTEB96/ ENGOT-ov65) | laura.polastro@hubruxelles.be | 3 | 3 | ||
| 22675 | Any line/RECIST v1.1/Eligible for platinium salt chemotherapy | Nuria Kotecki | Multiple | Onxeo | OX2016-203-01 | Trial closed | An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors | Nuria.Kotecki@hubruxelles.be | 1 | 1 | |
| 22647 | after one line | Alex De Caluwé | Multiple | UZ-Gent | PRIMMO trial - Pembrolizumab-Radiotherapy-Immunomodulator trial | Trial closed | A phase II Investigation of Pembrolizumab (Keytruda) in combination with radiation and an immune modulatory cocktail in patients with cervical and uterine cancer | accueil.cons.radiotherapie@hubruxelles.be | 2 | 2 |